智通财经APP讯，复宏汉霖(02696)发布公告，近日，公司自主研发的Perjeta®(帕妥珠单抗)生物类似药候选药HLX11(重组抗HER2结构域II人源化单克隆抗体注射液)的上市许可申请获欧洲药品管理局受理，本次申请涉及的适应症如下：(1)与曲妥珠单抗和化疗联合：用于 HER2阳性、局部晚期、炎性或早期乳腺癌且具有高复发风险成人患者的新辅助治疗;以及用于具有高复发风险的HER2阳性早期乳腺癌成人患者的辅助治疗;(2)与曲妥珠单抗和多西他赛联合：用于治疗既往未接受过针对转移性疾病抗HER2治疗或化疗的HER2阳性、转移性或局部复发不可切除乳腺癌成人患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.